Cognitive Effects of Immunomodulatory Drugs in MS
Completed
- Conditions
- Multiple Sclerosis
- Registration Number
- NCT00229502
- Lead Sponsor
- Sharon Lynch, MD
- Brief Summary
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).
- Detailed Description
In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
- Diagnosis of RRMS for at least one year,
- Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),
- Visual Acuity is 20/50 or better,
- patient has four color vision,
- Must have at least a high school education
Exclusion Criteria
- History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS,
- currently taking immunosuppressant medication,
- resides greater than 200 miles from the study site
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States